US 12,448,447 B2
CD8 binding agents
Nikolai Kley, Newton, MA (US); Jan Tavernier, Balegem (BE); Lennart Zabeau, Ghent (BE); and Erik Depla, Ghent (BE)
Assigned to Orionis Biosciences, Inc., Waltham, MA (US); and Orionis Biosciences BV, Ghent (BE)
Filed by Orionis Biosciences Inc., Waltham, MA (US); and Orionis Biosciences BV, Ghent (BE)
Filed on Dec. 1, 2022, as Appl. No. 18/060,694.
Application 18/060,694 is a continuation of application No. 16/634,325, granted, now 11,566,072, previously published as PCT/US2018/045741, filed on Aug. 8, 2018.
Claims priority of provisional application 62/542,920, filed on Aug. 9, 2017.
Prior Publication US 2023/0142099 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 14/56 (2006.01)
CPC C07K 16/2815 (2013.01) [C07K 14/56 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2319/02 (2013.01)] 14 Claims
 
1. A chimeric protein comprising a CD8 binding agent comprising:
(a) a targeting moiety having (i) an amino acid sequence having at least 90% identity with SEQ ID NO: 1217 and having a CDR3 consisting of the amino acid sequence of SEQ ID NO: 166; (ii) an amino acid sequence having at least 90% identity with SEQ ID NO: 1218 and having a CDR3 consisting of the amino acid sequence of SEQ ID NO: 177; (ii) an amino acid sequence having at least 90% identity with SEQ ID NO: 1219 and having a CDR3 consisting of the amino acid sequence of SEQ ID NO: 181; (iv) an amino acid sequence having at least 90% identity with SEQ ID NO: 1220 and having a CDR3 consisting of the amino acid sequence of SEQ ID NO: 199; or (v) an amino acid sequence having at least 90% identity with SEQ ID NO: 1216 and having a CDR3 consisting of the amino acid sequence of SEQ ID NO: 183, and
(b) a modified human interferon alpha 2 (IFN-α2) molecule having the amino acid sequence of SEQ ID NO: 288 or 289 and comprising a R149A mutation, relative to SEQ ID NO: 288 or 289, that confers reduced affinity or activity for its receptor, wherein the reduced affinity or activity at the receptor is restorable by attachment with the CD8 binding agent.